Serum Endothelial Cell–Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance: A Pilot Study. (April 2017)

• Record Type: Journal Article
• Authors: Qiu, Chong-Rong; Fu, Qiang; Sui, Jian; Zhang, Qian; Wei, Peng; Wu, Yan; Zhu, Ke; Lu, Yi; Zong, Bing
• Is Part Of: Angiology. Volume 68:Number 4(2017)
• Page Start: 354
• Page End: 359
• Publication Date: 2017-04
• Subjects: acute myocardial infarction -- endothelial cell–specific molecule 1 -- endocan -- inflammation -- Gensini score -- biomarker; Blood-vessels -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.13005
• DOI: 10.1177/0003319716651349
• Languages: English
• ISSNs: 0003-3197

Abstract

Endothelial dysfunction is involved in the process of acute myocardial infarction (AMI), that is, the endothelial cell–specific molecule 1 (ESM-1; endocan) is a novel endothelial dysfunction marker. However, the relationship between patients with AMI and serum ESM-1 levels is not very clear. Patients with AMI (n = 216) and a control group (n = 60) without AMI were included in the study. High-sensitivity C-reactive protein (hsCRP) was measured, and the severity of AMI was assessed by a modified Gensini stenosis scoring system. Serum ESM-1 levels were significantly higher in the AMI group ( P < .05). High-sensitivity C-reactive protein levels were also significantly higher in the AMI group ( P < .05). In patients with AMI, serum ESM-1 levels were not significantly correlated with hsCRP levels. There was no significant correlation between serum ESM-1 level and Gensini score. Our findings suggest that serum ESM-1 levels may be a novel biomarker of endothelial dysfunction in patients with AMI.